Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...

Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

The company's famous medicines, diabetes treatment Ozempic and anti-obesity medicine Wegovy, have been on fire. However, some investors are worried that Novo Nordisk will lose significant market ...

Novo Nordisk's work in the GLP-1 space has been instrumental to its success in recent years. The company's famous medicines, diabetes treatment Ozempic and anti-obesity medicine Wegovy ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Morgan Stanley began coverage on shares of Novo Nordisk A/S (NYSE:NVO – Free Report) in a research report released on ...

The manufacturer of the weight loss jab Wegovy has been reprimanded for allegedly failing to disclose or accurately report ...